El hierro es un elemento importante para una serie de funciones corporales fundamentales, una de las cuales, la capacidad cognitiva, es fundamental para los geeks.
Además, el hierro regula una serie de procesos, algunos de los cuales se muestran en la imagen.
En el artĂculo, descubriremos cuáles son las causas del desequilibrio de hierro, quĂ© pruebas tomar para controlar y cĂłmo mantener su nivel en el rango normal.
Homeostasis de hierro
, [1].
. 1. . (Fe) , (TF) ( , ).
(RBCs), , .
.
, [1].
(2 ) .
( 60% 80% ).
.
(2–4 ). , ( ) (20–25 ).
1–2 , 1–2 , , .
, -, , - .
, [1].
( ).
, , 50 % [2].
, , , .
, , ( ), , , (, ), ( , ) [1].
(, , , , – ( ) [3]) ( ) .
, , [4,5].
, , ().
, .
, . , , .
, .
- , .
, , [1].
, , ( ) .
.
( , )[6].
, , .
, ()- () . , , , [7].
, 1930- - 2-4 , 1 ( — , ).
, . -, .
.
[8].
, .
, .
(SF) (TST) (. 2):
1) , , . , - , . , .
2) β- , 1, .
1. [8].
– , – , ↓ -, ↑ — , ↓↓ — , — .
3) SF TST : (1) SF > 100 / TST 20–50%; (2) SF > 100 / TST < 20%; (3) SF < 30 / TST < 20%.
4) - .
5) . ( 3), . , () . , - .
6) . . — , [9]. , . . .
(.)
. 2. [9].
:
- , . — .
- , , , .
- (30-100 ) ( 2) .
- () .
- , ( ) . , , .
2. [8]. 1 .
/, , .
, . , , .
, , , , . .
, .
( 3).
3. [8]
.
– 10 – 30 ( 4).
4. .
, , , , . .
, , .
, , , , - , .
, , , , , .
, , , . C- ( , ) , , , .
, .
, .
.
Lifext ,
, . , .
Lifext.
— + .
, Google. Lifext, . ( ) + .
— 120. ( 1,9$, ). , . - , , .
, , ;)
-
[1] S. Dev, J.L. Babitt, Overview of iron metabolism in health and disease, Hemodial. Int. 21 (2017) S6–S20. doi:10.1111/hdi.12542.
[2] E. McLean, M. Cogswell, I. Egli, D. Wojdyla, B. De Benoist, Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005, Public Health Nutr. 12 (2009) 444–454. doi:10.1017/S1368980008002401.
[3] P. Guggenbuhl, Y. Deugnier, J.F. Boisdet, Y. Rolland, A. Perdriger, Y. Pawlotsky, G. Chalès, Bone mineral density in men with genetic hemochromatosis and HFE gene mutation, Osteoporos. Int. 16 (2005) 1809–1814. doi:10.1007/s00198-005-1934-0.
[4] A.L. Fracanzani, D. Conte, M. Fraquelli, E. Taioli, M. Mattioli, A. Losco, S. Fargion, Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease, Hepatology. 33 (2001) 647–651. doi:10.1053/jhep.2001.22506.
[5] C. Borgna-Pignatti, G. Vergine, T. Lombardo, M.D. Cappellini, P. Cianciulli, A. Maggio, D. Renda, M.E. Lai, A. Mandas, G. Forni, A. Piga, M.G. Bisconte, Hepatocellular carcinoma in the thalassaemia syndromes, Br. J. Haematol. 124 (2004) 114–117. doi:10.1046/j.1365-2141.2003.04732.x.
[6] A. Poujois, J.C. Devedjian, C. Moreau, D. Devos, P. Chaine, F. Woimant, J.A. Duce, Bioavailable Trace Metals in Neurological Diseases, Curr. Treat. Options Neurol. 18 (2016). doi:10.1007/s11940-016-0426-1.
[7] M.J. Murray, A.B. Murray, M.B. Murray, C.J. Murray, The adverse effect of iron repletion on the course of certain infections, Br. Med. J. 2 (1978) 1113–1115. doi:10.1136/bmj.2.6145.1113.
[8] M.S.Y. Low, G. Grigoriadis, Iron deficiency and new insights into therapy, Med. J. Aust. 207 (2017) 81–87. doi:10.5694/mja16.01304.
[9] L. De Franceschi, A. Iolascon, A. Taher, M.D. Cappellini, Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment, Eur. J. Intern. Med. 42 (2017) 16–23. doi:10.1016/j.ejim.2017.04.018.